nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—ALB—focal segmental glomerulosclerosis	0.538	1	CbGaD
Clomipramine—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.0588	0.328	CbGbCtD
Clomipramine—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0474	0.265	CbGbCtD
Clomipramine—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.0447	0.249	CbGbCtD
Clomipramine—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0284	0.158	CbGbCtD
Clomipramine—Infection susceptibility increased—Cyclosporine—focal segmental glomerulosclerosis	0.0235	0.0937	CcSEcCtD
Clomipramine—Fibroadenosis of breast—Cyclosporine—focal segmental glomerulosclerosis	0.0105	0.0417	CcSEcCtD
Clomipramine—Fibroadenoma of breast—Cyclosporine—focal segmental glomerulosclerosis	0.00976	0.0389	CcSEcCtD
Clomipramine—Vestibular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00706	0.0281	CcSEcCtD
Clomipramine—Salivary gland enlargement—Cyclosporine—focal segmental glomerulosclerosis	0.0051	0.0203	CcSEcCtD
Clomipramine—Toxicity to various agents—Cyclosporine—focal segmental glomerulosclerosis	0.00496	0.0198	CcSEcCtD
Clomipramine—Pharyngeal oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00496	0.0198	CcSEcCtD
Clomipramine—Sensation of foreign body—Cyclosporine—focal segmental glomerulosclerosis	0.00435	0.0173	CcSEcCtD
Clomipramine—Uterine haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00405	0.0162	CcSEcCtD
Clomipramine—Goitre—Cyclosporine—focal segmental glomerulosclerosis	0.00397	0.0158	CcSEcCtD
Clomipramine—Peripheral ischaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00388	0.0155	CcSEcCtD
Clomipramine—Paresis—Cyclosporine—focal segmental glomerulosclerosis	0.00388	0.0155	CcSEcCtD
Clomipramine—Hypertrichosis—Cyclosporine—focal segmental glomerulosclerosis	0.00373	0.0149	CcSEcCtD
Clomipramine—Pyelonephritis—Cyclosporine—focal segmental glomerulosclerosis	0.00373	0.0149	CcSEcCtD
Clomipramine—Leukorrhea—Cyclosporine—focal segmental glomerulosclerosis	0.00302	0.012	CcSEcCtD
Clomipramine—Myositis—Cyclosporine—focal segmental glomerulosclerosis	0.00289	0.0115	CcSEcCtD
Clomipramine—Gingival bleeding—Cyclosporine—focal segmental glomerulosclerosis	0.0025	0.00995	CcSEcCtD
Clomipramine—Multiple fractures—Cyclosporine—focal segmental glomerulosclerosis	0.00244	0.00972	CcSEcCtD
Clomipramine—Fracture—Cyclosporine—focal segmental glomerulosclerosis	0.00244	0.00972	CcSEcCtD
Clomipramine—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00244	0.00972	CcSEcCtD
Clomipramine—Cerebration impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00241	0.0096	CcSEcCtD
Clomipramine—Vaginal discharge—Cyclosporine—focal segmental glomerulosclerosis	0.00233	0.00928	CcSEcCtD
Clomipramine—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.00225	0.00898	CcSEcCtD
Clomipramine—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.00225	0.00898	CcSEcCtD
Clomipramine—Encephalopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00221	0.0088	CcSEcCtD
Clomipramine—Tooth disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00218	0.00871	CcSEcCtD
Clomipramine—Peptic ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00212	0.00845	CcSEcCtD
Clomipramine—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00208	0.00828	CcSEcCtD
Clomipramine—HTR2A—arteriole—focal segmental glomerulosclerosis	0.00204	0.41	CbGeAlD
Clomipramine—Myopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00202	0.00805	CcSEcCtD
Clomipramine—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00182	0.00725	CcSEcCtD
Clomipramine—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00719	CcSEcCtD
Clomipramine—Hyperaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00719	CcSEcCtD
Clomipramine—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00168	0.00671	CcSEcCtD
Clomipramine—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00652	CcSEcCtD
Clomipramine—Breast pain—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.00647	CcSEcCtD
Clomipramine—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00161	0.00643	CcSEcCtD
Clomipramine—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.0016	0.00638	CcSEcCtD
Clomipramine—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00157	0.00625	CcSEcCtD
Clomipramine—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00621	CcSEcCtD
Clomipramine—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00621	CcSEcCtD
Clomipramine—Arthropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00621	CcSEcCtD
Clomipramine—Glossitis—Cyclosporine—focal segmental glomerulosclerosis	0.00154	0.00613	CcSEcCtD
Clomipramine—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00609	CcSEcCtD
Clomipramine—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00609	CcSEcCtD
Clomipramine—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.00152	0.00605	CcSEcCtD
Clomipramine—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00575	CcSEcCtD
Clomipramine—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.00565	CcSEcCtD
Clomipramine—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.00555	CcSEcCtD
Clomipramine—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00545	CcSEcCtD
Clomipramine—Nightmare—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00545	CcSEcCtD
Clomipramine—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.0053	CcSEcCtD
Clomipramine—Cramps of lower extremities—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.00519	CcSEcCtD
Clomipramine—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00516	CcSEcCtD
Clomipramine—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00516	CcSEcCtD
Clomipramine—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.0051	CcSEcCtD
Clomipramine—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00505	CcSEcCtD
Clomipramine—Abnormal vision—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.00492	CcSEcCtD
Clomipramine—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.0049	CcSEcCtD
Clomipramine—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.0048	CcSEcCtD
Clomipramine—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00471	CcSEcCtD
Clomipramine—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.00467	CcSEcCtD
Clomipramine—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00458	CcSEcCtD
Clomipramine—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00458	CcSEcCtD
Clomipramine—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00458	CcSEcCtD
Clomipramine—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00456	CcSEcCtD
Clomipramine—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00454	CcSEcCtD
Clomipramine—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00438	CcSEcCtD
Clomipramine—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00436	CcSEcCtD
Clomipramine—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00434	CcSEcCtD
Clomipramine—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00425	CcSEcCtD
Clomipramine—Anaphylactoid reaction—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.00423	CcSEcCtD
Clomipramine—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.0042	CcSEcCtD
Clomipramine—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.0041	CcSEcCtD
Clomipramine—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.00403	CcSEcCtD
Clomipramine—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.00403	CcSEcCtD
Clomipramine—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.000974	0.00388	CcSEcCtD
Clomipramine—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.000943	0.00376	CcSEcCtD
Clomipramine—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000929	0.0037	CcSEcCtD
Clomipramine—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00091	0.00363	CcSEcCtD
Clomipramine—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.000907	0.00361	CcSEcCtD
Clomipramine—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000889	0.00354	CcSEcCtD
Clomipramine—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.000874	0.00348	CcSEcCtD
Clomipramine—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.000866	0.00345	CcSEcCtD
Clomipramine—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.000855	0.00341	CcSEcCtD
Clomipramine—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.000831	0.00331	CcSEcCtD
Clomipramine—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.000821	0.00327	CcSEcCtD
Clomipramine—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.000809	0.00322	CcSEcCtD
Clomipramine—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000804	0.0032	CcSEcCtD
Clomipramine—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000802	0.0032	CcSEcCtD
Clomipramine—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000797	0.00318	CcSEcCtD
Clomipramine—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00079	0.00315	CcSEcCtD
Clomipramine—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.000781	0.00311	CcSEcCtD
Clomipramine—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000777	0.0031	CcSEcCtD
Clomipramine—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000777	0.0031	CcSEcCtD
Clomipramine—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000773	0.00308	CcSEcCtD
Clomipramine—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00077	0.00307	CcSEcCtD
Clomipramine—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00077	0.00307	CcSEcCtD
Clomipramine—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.000756	0.00301	CcSEcCtD
Clomipramine—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00075	0.00299	CcSEcCtD
Clomipramine—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000748	0.00298	CcSEcCtD
Clomipramine—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000744	0.00296	CcSEcCtD
Clomipramine—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000713	0.00284	CcSEcCtD
Clomipramine—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000711	0.00284	CcSEcCtD
Clomipramine—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000708	0.00282	CcSEcCtD
Clomipramine—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000706	0.00281	CcSEcCtD
Clomipramine—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000703	0.0028	CcSEcCtD
Clomipramine—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000699	0.00279	CcSEcCtD
Clomipramine—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000697	0.00278	CcSEcCtD
Clomipramine—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000686	0.00273	CcSEcCtD
Clomipramine—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000663	0.00264	CcSEcCtD
Clomipramine—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00066	0.00263	CcSEcCtD
Clomipramine—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000645	0.00257	CcSEcCtD
Clomipramine—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000641	0.00256	CcSEcCtD
Clomipramine—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000638	0.00254	CcSEcCtD
Clomipramine—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000636	0.00253	CcSEcCtD
Clomipramine—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000629	0.00251	CcSEcCtD
Clomipramine—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000623	0.00248	CcSEcCtD
Clomipramine—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000619	0.00247	CcSEcCtD
Clomipramine—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00061	0.00243	CcSEcCtD
Clomipramine—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.000608	0.00242	CcSEcCtD
Clomipramine—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000606	0.00242	CcSEcCtD
Clomipramine—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.000602	0.0024	CcSEcCtD
Clomipramine—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000595	0.00237	CcSEcCtD
Clomipramine—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000584	0.00233	CcSEcCtD
Clomipramine—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00058	0.00231	CcSEcCtD
Clomipramine—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000575	0.00229	CcSEcCtD
Clomipramine—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000572	0.00228	CcSEcCtD
Clomipramine—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.000569	0.00227	CcSEcCtD
Clomipramine—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000559	0.00223	CcSEcCtD
Clomipramine—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000556	0.00222	CcSEcCtD
Clomipramine—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000554	0.00221	CcSEcCtD
Clomipramine—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00054	0.00215	CcSEcCtD
Clomipramine—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000537	0.00214	CcSEcCtD
Clomipramine—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000535	0.00213	CcSEcCtD
Clomipramine—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000527	0.0021	CcSEcCtD
Clomipramine—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000527	0.0021	CcSEcCtD
Clomipramine—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000527	0.0021	CcSEcCtD
Clomipramine—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000525	0.00209	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000524	0.00209	CcSEcCtD
Clomipramine—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000521	0.00208	CcSEcCtD
Clomipramine—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000516	0.00206	CcSEcCtD
Clomipramine—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00051	0.00203	CcSEcCtD
Clomipramine—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000505	0.00201	CcSEcCtD
Clomipramine—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000505	0.00201	CcSEcCtD
Clomipramine—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000496	0.00198	CcSEcCtD
Clomipramine—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000495	0.00197	CcSEcCtD
Clomipramine—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000491	0.00196	CcSEcCtD
Clomipramine—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000489	0.00195	CcSEcCtD
Clomipramine—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000482	0.00192	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000461	0.00184	CcSEcCtD
Clomipramine—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000457	0.00182	CcSEcCtD
Clomipramine—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000454	0.00181	CcSEcCtD
Clomipramine—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000451	0.0018	CcSEcCtD
Clomipramine—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000449	0.00179	CcSEcCtD
Clomipramine—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000445	0.00177	CcSEcCtD
Clomipramine—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000439	0.00175	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000436	0.00174	CcSEcCtD
Clomipramine—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000436	0.00174	CcSEcCtD
Clomipramine—GSTP1—nephron tubule—focal segmental glomerulosclerosis	0.000435	0.0876	CbGeAlD
Clomipramine—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000432	0.00172	CcSEcCtD
Clomipramine—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000432	0.00172	CcSEcCtD
Clomipramine—HTR2A—endothelium—focal segmental glomerulosclerosis	0.000418	0.0842	CbGeAlD
Clomipramine—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000417	0.00166	CcSEcCtD
Clomipramine—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000413	0.00165	CcSEcCtD
Clomipramine—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000402	0.0016	CcSEcCtD
Clomipramine—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.0004	0.00159	CcSEcCtD
Clomipramine—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.0004	0.00159	CcSEcCtD
Clomipramine—GSTP1—kidney—focal segmental glomerulosclerosis	0.000382	0.0769	CbGeAlD
Clomipramine—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000372	0.00148	CcSEcCtD
Clomipramine—GSTP1—cortex of kidney—focal segmental glomerulosclerosis	0.000372	0.0749	CbGeAlD
Clomipramine—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000363	0.00145	CcSEcCtD
Clomipramine—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000358	0.00143	CcSEcCtD
Clomipramine—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000346	0.00138	CcSEcCtD
Clomipramine—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000334	0.00133	CcSEcCtD
Clomipramine—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000321	0.00128	CcSEcCtD
Clomipramine—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000319	0.00127	CcSEcCtD
Clomipramine—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000318	0.00127	CcSEcCtD
Clomipramine—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000317	0.00126	CcSEcCtD
Clomipramine—HTR2B—cortex of kidney—focal segmental glomerulosclerosis	0.000307	0.0618	CbGeAlD
Clomipramine—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.0003	0.0012	CcSEcCtD
Clomipramine—ADRA2A—cortex of kidney—focal segmental glomerulosclerosis	0.000193	0.0388	CbGeAlD
Clomipramine—HTR2A—kidney—focal segmental glomerulosclerosis	0.000168	0.0339	CbGeAlD
Clomipramine—Acepromazine—ALB—focal segmental glomerulosclerosis	0.000157	0.189	CrCbGaD
Clomipramine—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000156	0.0314	CbGeAlD
Clomipramine—CYP2D6—kidney—focal segmental glomerulosclerosis	0.000153	0.0309	CbGeAlD
Clomipramine—Thioproperazine—ALB—focal segmental glomerulosclerosis	0.000153	0.185	CrCbGaD
Clomipramine—Pipotiazine—ALB—focal segmental glomerulosclerosis	0.000151	0.182	CrCbGaD
Clomipramine—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000125	0.0253	CbGeAlD
Clomipramine—Nortriptyline—ALB—focal segmental glomerulosclerosis	0.000116	0.141	CrCbGaD
Clomipramine—ABCB1—kidney—focal segmental glomerulosclerosis	0.00011	0.0222	CbGeAlD
Clomipramine—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000107	0.0216	CbGeAlD
Clomipramine—Diazepam—ALB—focal segmental glomerulosclerosis	8.8e-05	0.106	CrCbGaD
Clomipramine—Chlorpromazine—ALB—focal segmental glomerulosclerosis	8.17e-05	0.0987	CrCbGaD
Clomipramine—Amitriptyline—ALB—focal segmental glomerulosclerosis	8.08e-05	0.0976	CrCbGaD
Clomipramine—ADRA2A—Hemostasis—TRPC6—focal segmental glomerulosclerosis	4.5e-05	0.00171	CbGpPWpGaD
Clomipramine—ADRA2A—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	4.47e-05	0.0017	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	4.46e-05	0.0017	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	4.44e-05	0.00169	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	4.44e-05	0.00169	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	4.43e-05	0.00168	CbGpPWpGaD
Clomipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	4.42e-05	0.00168	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	4.42e-05	0.00168	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	4.34e-05	0.00165	CbGpPWpGaD
Clomipramine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	4.29e-05	0.00163	CbGpPWpGaD
Clomipramine—HTR2B—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	4.25e-05	0.00162	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	4.23e-05	0.00161	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	4.22e-05	0.00161	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	4.19e-05	0.0016	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	4.13e-05	0.00157	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	4.13e-05	0.00157	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	4.09e-05	0.00156	CbGpPWpGaD
Clomipramine—ALB—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	4.06e-05	0.00154	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	4.05e-05	0.00154	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	4.03e-05	0.00153	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	3.97e-05	0.00151	CbGpPWpGaD
Clomipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	3.91e-05	0.00149	CbGpPWpGaD
Clomipramine—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	3.87e-05	0.00147	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	3.85e-05	0.00147	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	3.85e-05	0.00146	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—GNAQ—focal segmental glomerulosclerosis	3.76e-05	0.00143	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	3.75e-05	0.00143	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	3.74e-05	0.00142	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	3.73e-05	0.00142	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	3.71e-05	0.00141	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	3.61e-05	0.00137	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	3.61e-05	0.00137	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	3.6e-05	0.00137	CbGpPWpGaD
Clomipramine—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	3.59e-05	0.00137	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	3.59e-05	0.00136	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	3.58e-05	0.00136	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.57e-05	0.00136	CbGpPWpGaD
Clomipramine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	3.56e-05	0.00135	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	3.55e-05	0.00135	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—LPL—focal segmental glomerulosclerosis	3.45e-05	0.00131	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	3.43e-05	0.00131	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	3.43e-05	0.0013	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	3.43e-05	0.0013	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.42e-05	0.0013	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	3.41e-05	0.0013	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.4e-05	0.00129	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	3.4e-05	0.00129	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	3.39e-05	0.00129	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	3.38e-05	0.00129	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3.33e-05	0.00127	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	3.27e-05	0.00124	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	3.26e-05	0.00124	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.26e-05	0.00124	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	3.25e-05	0.00124	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	3.17e-05	0.00121	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	3.13e-05	0.00119	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	3.12e-05	0.00119	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	3.11e-05	0.00118	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	3.11e-05	0.00118	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	3.1e-05	0.00118	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.08e-05	0.00117	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	3.01e-05	0.00115	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.99e-05	0.00114	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	2.98e-05	0.00113	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	2.97e-05	0.00113	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—AGT—focal segmental glomerulosclerosis	2.95e-05	0.00112	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	2.94e-05	0.00112	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.93e-05	0.00112	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	2.89e-05	0.0011	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	2.88e-05	0.0011	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.86e-05	0.00109	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	2.85e-05	0.00108	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	2.85e-05	0.00108	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	2.84e-05	0.00108	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	2.83e-05	0.00108	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	2.82e-05	0.00107	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	2.75e-05	0.00105	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	2.73e-05	0.00104	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	2.71e-05	0.00103	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	2.7e-05	0.00103	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.69e-05	0.00103	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	2.67e-05	0.00102	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.63e-05	0.001	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	2.63e-05	0.001	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	2.63e-05	0.001	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.63e-05	0.000999	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.62e-05	0.000998	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.62e-05	0.000995	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	2.61e-05	0.000995	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.61e-05	0.000992	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	2.58e-05	0.000983	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	2.57e-05	0.000977	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.53e-05	0.000961	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	2.5e-05	0.000951	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	2.46e-05	0.000934	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	2.4e-05	0.000914	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.39e-05	0.000911	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	2.39e-05	0.00091	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	2.39e-05	0.000909	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.38e-05	0.000906	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	2.38e-05	0.000905	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	2.37e-05	0.000903	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	2.33e-05	0.000888	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.33e-05	0.000887	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.28e-05	0.000868	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	2.28e-05	0.000868	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—ALB—focal segmental glomerulosclerosis	2.26e-05	0.000861	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—FN1—focal segmental glomerulosclerosis	2.24e-05	0.000851	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.22e-05	0.000843	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—NOS2—focal segmental glomerulosclerosis	2.21e-05	0.000841	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.19e-05	0.000834	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	2.18e-05	0.00083	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	2.18e-05	0.000828	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	2.17e-05	0.000826	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	2.16e-05	0.000822	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.15e-05	0.000818	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	2.12e-05	0.000806	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.08e-05	0.00079	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.05e-05	0.000781	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.04e-05	0.000775	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.03e-05	0.000774	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	2.03e-05	0.000771	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.01e-05	0.000763	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2e-05	0.000762	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	1.98e-05	0.000752	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	1.94e-05	0.000737	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.93e-05	0.000735	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.92e-05	0.000731	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—LIPC—focal segmental glomerulosclerosis	1.88e-05	0.000716	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.86e-05	0.000708	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—ALB—focal segmental glomerulosclerosis	1.86e-05	0.000707	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	1.84e-05	0.000702	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	1.84e-05	0.0007	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.84e-05	0.0007	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.83e-05	0.000697	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.83e-05	0.000695	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	1.8e-05	0.000685	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	1.77e-05	0.000674	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	1.77e-05	0.000672	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	1.76e-05	0.000669	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	1.75e-05	0.000664	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.74e-05	0.000662	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.7e-05	0.000647	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.7e-05	0.000647	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	1.68e-05	0.00064	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.68e-05	0.000638	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	1.67e-05	0.000637	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.67e-05	0.000635	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CTGF—focal segmental glomerulosclerosis	1.66e-05	0.00063	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.65e-05	0.000628	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.61e-05	0.000614	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.56e-05	0.000594	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.56e-05	0.000594	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.55e-05	0.00059	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	1.53e-05	0.000582	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	1.53e-05	0.000581	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.53e-05	0.000581	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.53e-05	0.00058	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.52e-05	0.000577	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.51e-05	0.000573	CbGpPWpGaD
Clomipramine—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	1.48e-05	0.000565	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.48e-05	0.000562	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.47e-05	0.000559	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.43e-05	0.000543	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.42e-05	0.000541	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.41e-05	0.000538	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.41e-05	0.000537	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.4e-05	0.000534	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	1.39e-05	0.000529	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	1.33e-05	0.000507	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	1.31e-05	0.000497	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.3e-05	0.000496	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.3e-05	0.000495	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.29e-05	0.00049	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.28e-05	0.000488	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.28e-05	0.000485	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.25e-05	0.000476	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	1.23e-05	0.000466	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.22e-05	0.000463	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.21e-05	0.000462	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.2e-05	0.000458	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.2e-05	0.000456	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.19e-05	0.000453	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.18e-05	0.000447	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	1.17e-05	0.000446	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.17e-05	0.000444	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.15e-05	0.000438	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—LPL—focal segmental glomerulosclerosis	1.15e-05	0.000437	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.15e-05	0.000436	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.11e-05	0.000423	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.09e-05	0.000414	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.09e-05	0.000413	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.08e-05	0.000412	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.08e-05	0.000411	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	1.08e-05	0.000411	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.06e-05	0.000401	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.06e-05	0.000401	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.04e-05	0.000395	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	1.04e-05	0.000395	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	9.99e-06	0.00038	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.94e-06	0.000378	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.91e-06	0.000377	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	9.89e-06	0.000376	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—AGT—focal segmental glomerulosclerosis	9.82e-06	0.000374	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—FN1—focal segmental glomerulosclerosis	9.6e-06	0.000365	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	9.6e-06	0.000365	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	9.34e-06	0.000355	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	9.28e-06	0.000353	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	9.14e-06	0.000348	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	9.09e-06	0.000346	CbGpPWpGaD
Clomipramine—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	9.06e-06	0.000345	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	9.03e-06	0.000343	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.93e-06	0.00034	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	8.42e-06	0.00032	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	8.34e-06	0.000317	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.31e-06	0.000316	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	8.21e-06	0.000312	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	8.13e-06	0.000309	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	8.01e-06	0.000305	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	7.99e-06	0.000304	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	7.94e-06	0.000302	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	7.75e-06	0.000295	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.59e-06	0.000289	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	7.59e-06	0.000289	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—ALB—focal segmental glomerulosclerosis	7.54e-06	0.000287	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	7.48e-06	0.000285	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	7.06e-06	0.000268	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	6.96e-06	0.000265	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	6.94e-06	0.000264	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.85e-06	0.000261	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	6.79e-06	0.000258	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.5e-06	0.000247	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	6.4e-06	0.000243	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	6.34e-06	0.000241	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	6.31e-06	0.00024	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.25e-06	0.000238	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	6.12e-06	0.000233	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	5.42e-06	0.000206	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	5.34e-06	0.000203	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.32e-06	0.000202	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	5.21e-06	0.000198	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.04e-06	0.000192	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	4.91e-06	0.000187	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	4.89e-06	0.000186	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.84e-06	0.000184	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.38e-06	0.000167	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	4.18e-06	0.000159	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	4.16e-06	0.000158	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.99e-06	0.000152	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	3.21e-06	0.000122	CbGpPWpGaD
